Novo Nordisk Eyes Pediatric Approval After 0.83% HbA1c Reduction and 72% Stock Fall
The PIONEER TEENS trial found Novo Nordisk’s oral semaglutide lowered HbA1c by 0.83% versus placebo in 10–17-year-olds with type 2 diabetes, supporting planned U.S. and EU pediatric filings in H2 2026. Shares have fallen 72% from peaks due to decelerating GLP-1 growth and rising Eli Lilly competition, raising valuation concerns despite the pipeline.
1. Pediatric Trial Success
The PIONEER TEENS phase 3a trial in 10–17-year-olds with type 2 diabetes showed oral semaglutide reduced HbA1c by 0.83% versus placebo, meeting its primary endpoint and demonstrating significant glycemic control in a pediatric population.
2. Planned Regulatory Filings
Novo Nordisk plans to file for pediatric label expansion in the U.S. and EU in H2 2026 based on these positive results, positioning oral semaglutide as the first potential GLP-1 therapy approved for young patients with type 2 diabetes.
3. Stock Slide and Competitive Challenges
Shares have plunged 72% from peak levels amid slowing GLP-1 growth and intensifying competition from Eli Lilly’s pipeline, fueling investor concern over valuation despite Novo Nordisk’s extensive development programs.